MINT-Irbesartan/HCTZ Product Recall (2021-05-26)
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I
MINT-Irbesartan/HCTZ 150/12.5 mg Tablet
| Lot or serial number | Companies | Brand name | DIN, NPN, DIN-HIM | Dosage form | Strength |
|---|
| 1805011402 | - Recalling Firm
- Mint Pharmaceuticals Inc
- 6575 Davand Drive
- Mississauga
- L5T 2M3
- Ontario
- CANADA
- Marketing Authorization Holder
- Mint Pharmaceuticals Inc
- 6575 Davand Drive
- Mississauga
- L5T 2M3
- Ontario
- CANADA
| B. MINT-Irbesartan/HCTZ 300/12.5 mg Tablet | DIN 02393018 | Tablet | Irbesartan 300 mg |
| 1805011576 | - Recalling Firm
- Mint Pharmaceuticals Inc
- 6575 Davand Drive
- Mississauga
- L5T 2M3
- Ontario
- CANADA
- Marketing Authorization Holder
- Mint Pharmaceuticals Inc
- 6575 Davand Drive
- Mississauga
- L5T 2M3
- Ontario
- CANADA
| C. MINT-Irbesartan/HCTZ 300/25 mg Tablet | DIN 02393026 | Tablet | Irbesartan 300 mg |
| 1805011398 | - Recalling Firm
- Mint Pharmaceuticals Inc
- 6575 Davand Drive
- Mississauga
- L5T 2M3
- Ontario
- CANADA
- Marketing Authorization Holder
- Mint Pharmaceuticals Inc
- 6575 Davand Drive
- Mississauga
- L5T 2M3
- Ontario
- CANADA
| A. MINT-Irbesartan/HCTZ 150/12.5 mg Tablet | DIN 02392992 | Tablet | Irbesartan 150 mg |
-
MINT-Irbesartan/HCTZ 150/12.5 mg Tablet
-
MINT-Irbesartan/HCTZ 300/12.5 mg Tablet
-
MINT-Irbesartan/HCTZ 300/25 mg Tablet
Presence of impurity 5-(4-(azidomethyl)-[1,1-biphenyl]-2-yl)-1H-tetrazole above the acceptable concentration limit in affected lots.